According to Fortune Business Insights, the global digital pathology market size was valued at USD 1.30 billion in 2025 and is projected to grow from USD 1.47 billion in 2026 to USD 5.75 billion by 2034, exhibiting a CAGR of 18.56% during the forecast period from 2026 to 2034. North America held the leading position with a 36.74% market share in 2025.
The strong projected growth reflects increasing digitization across pathology workflows, rising adoption of advanced diagnostic technologies, and the growing need to manage higher pathology workloads efficiently.
Digital pathology provides a digital alternative to conventional pathology workflows by converting pathology slides into digital formats that can be analyzed and accessed electronically. The technology can support remote reviewing, image analysis, workflow management, data storage, and high-throughput applications.
The COVID-19 pandemic accelerated the digitization of pathology systems. The market recorded a growth rate of 31.2% in 2020, compared with 11.6% in 2019, as social distancing measures reduced in-person consultations and encouraged the adoption of remote pathology solutions. Regulatory actions also supported adoption, including a U.S. FDA policy introduced in April 2020 that expanded the availability of digital pathology devices for remote review and reporting.
For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/digital-pathology-market-100229
The integration of Artificial Intelligence (AI) is one of the major trends shaping the digital pathology market. AI-based tools are increasingly being used for workflow management, image analysis, and assisted pathology. Companies are developing machine-learning and deep-learning solutions to meet the demand for advanced pathology technologies.
The source highlights several developments in this area. In December 2021, F. Hoffmann-La Roche Ltd. launched three AI-based digital pathology algorithms for deep-learning image analysis. In September 2023, Sigtuple received U.S. FDA approval for a blood smear application used in AI-assisted digital microscopy.
The increasing demand to digitize pathology workflows is encouraging companies to develop tools that streamline workloads and customize solutions. Strategic collaborations, product launches, and investments in AI-powered pathology platforms are further supporting this trend.
The increasing incidence of chronic diseases is driving demand for pathology testing and, consequently, digital pathology products. A higher number of diagnostic tests increases the workload for pathologists, creating demand for digital tools that can improve workflow efficiency and support diagnostic activities.
Growing applications of digital pathology in disease diagnosis, predictive analysis, and drug discovery are supporting market expansion. Increasing regulatory approvals and government-funded research programs focused on digital pathology innovation are also expected to encourage adoption.
Digital pathology is increasingly being applied to drug discovery and high-throughput screening. The growing demand for potential pipeline drugs for life-threatening diseases is expected to make drug discovery one of the fastest-growing applications during the forecast period.